July 30, 2021 - ROSEN LOGO.jpg
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
19 févr. 2024 16h53 HE | The Rosen Law Firm PA
NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...
Telehealth Evolution
Telehealth Evolution: Weightox Rx Enhances Access to Established Semaglutide Treatment for Modern Weight Loss
15 janv. 2024 14h38 HE | Weightox Rx
Austin, Texas, Jan. 15, 2024 (GLOBE NEWSWIRE) -- In the evolving world of healthcare, telehealth solutions are significantly impacting how individuals access medical assistance, offering enhanced...
PG LOGO 1200x628px.jpg
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
21 déc. 2023 21h16 HE | Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
28 nov. 2023 08h00 HE | Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine
11 nov. 2023 08h31 HE | Novo Nordisk A/S
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity...
Sagimet-Logo-for-light-bg-FIN.png
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
10 nov. 2023 08h30 HE | Sagimet Biosciences Inc.
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...
Telegenixx.png
Workplace Weight Loss & Wellness Program Unveiled
04 oct. 2023 13h27 HE | Telegenixx
Telegenix's New Program Enables Employers to Provide Access to Pharma-Assisted Weight Loss at a Cost of $299 per Month, 70% Below the Industry Average
new_logo.png
GLP-1 Receptor Agonist Market to reach USD 55.8 billion by 2032, Says Graphical Research Powered by GMI
13 juin 2023 17h30 HE | Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- GLP-1 Receptor Agonist Market size is estimated to amass USD 55.8 billion by 2032. The industry is set to observe notable growth driven...
ST. PETE MEDICAL GROUP
Over 20 Million Suffer From Peripheral Neuropathy, St. Pete Medical Group Aims to Help
14 déc. 2022 12h30 HE | St. Pete Medical Group
ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live. Dr. Alex Spinoso announced their mission...